Disease · MONDO_0003529
Comparisons in its trials89
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 89
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TBP-PI-HBr vs Imipenem-cilastatin: deaths from any cause | 2 of 843 | 2 of 844 | 1,687 | NCT06059846 | Trial comparisons |
| TBP-PI-HBr vs Imipenem-cilastatin: serious adverse events | 29 of 843 | 22 of 844 | 1,687 | NCT06059846 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population | 176 of 685 | 176 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: deaths from any cause | 0 of 685 | 0 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: serious adverse events | 14 of 685 | 12 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations | 673 of 677 | 665 of 674 | 1,351 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC in the CE-TOC Populations | 611 of 641 | 617 of 637 | 1,278 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Sustained Clinical Cure at LFU in the CE-LFU Populations | 556 of 596 | 559 of 596 | 1,192 | NCT03788967 | Trial comparisons |
| CAZ-AVI vs Doripenem: serious adverse events | 21 of 511 | 12 of 509 | 1,020 | NCT01595438 | Trial comparisons |
| CAZ-AVI vs Doripenem: serious adverse events | 21 of 511 | 12 of 509 | 1,020 | NCT01599806 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population | 264 of 449 | 258 of 419 | 868 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT in the ME-EOT Populations | 437 of 439 | 394 of 401 | 840 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: By-Patient Microbiological Eradication at EOT in the ME-EOT Populations | 436 of 439 | 399 of 401 | 840 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC Days in the ME-TOC Populations | 390 of 413 | 363 of 376 | 789 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: By-Patient Microbiological Eradication at TOC in the ME-TOC Population | 257 of 413 | 254 of 376 | 789 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Overall Response (Combined Clinical Cure Plus Microbiological Eradication) At Test-Of-Cure (TOC) In The Microbiologically Evaluable (ME) - TOC Population | 254 of 413 | 247 of 376 | 789 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: By-Patient Sustained Microbiological Eradication at LFU Days in the ME-LFU Populations | 234 of 391 | 216 of 353 | 744 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Sustained Clinical Cure at LFU in the ME-LFU Population | 360 of 391 | 329 of 353 | 744 | NCT03788967 | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Number of Patients With Treatment-Emergent Adverse Events | 156 of 440 | 63 of 217 | 657 | NCT03840148 | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Number of Patients With Serious Adverse Events | 9 of 440 | 4 of 217 | 657 | NCT03840148 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003529/comparisons